Ingenol mebutate (Picato) for the cutaneous treatment of actinic keratosis

The WAR has drawn up a pharmacotherapeutic report for the medicine ingenol mebutate (Picato). Its therapeutic value was determined via comparison with 5-fluorouracil, imiquimod (5%), photodynamic therapy in combination with methyl aminolevulinate and photodynamic therapy in combination with 5-aminolevulinic acid. They reached the following conclusions:  the therapeutic value of ingenol mebutate is equal to that of 5-fluorouracil, imiquimod (5%), photodynamic therapy in combination with methyl aminolevulinate and photodynamic therapy in combination with 5-aminolevulinate for the topical treatment of nonhyperkeratotic, non-hypertrophic, actinic keratosis in adults who have multiple lesions or solitary lesion(s) that are less suited to treatment with cryotherapy.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.